FUJIFILM Cellular Dynamics
Fujifilm Cellular Dynamics leverages human iPSC technology to revolutionize scientific research and cell therapy. The company develops and manufactures human induced pluripotent stem cells (iPSCs) and related products for applications in disease modeling, drug discovery, toxicology, and stem cell banking. They also provide a wide range of neural, cardiac, hematopoietic, and accessory cell products, supporting biomedical research and therapeutic development. Their mission is to advance human health through innovative cell-based solutions, and their vision is to be a leader in human cell technology for research and regenerative medicine.
Industries
Nr. of Employees
medium (51-250)
FUJIFILM Cellular Dynamics
Madison, Wisconsin, United States, North America
Patents
Methods for directed differentiation of pluripotent stem cells to immune cells
US-12129486-B2
View DetailsMethod for reproducible differentiation of clinical-grade retinal pigment epithelium cells
US-12065671-B2
View Details
Methods for directed differentiation of pluripotent stem cells to immune cells
US-12129486-B2
View DetailsMethod for reproducible differentiation of clinical-grade retinal pigment epithelium cells
US-12065671-B2
View DetailsProducts
Assay-ready human iPSC-derived cardiomyocytes
Highly pure, terminally differentiated cardiomyocytes produced from human iPSCs and formatted for in vitro safety pharmacology and arrhythmia liability testing; compatible with multielectrode array and other electrophysiology platforms.
Assay-ready human iPSC-derived hepatocytes
Characterized hepatocyte populations derived from iPSCs with genotyping for ADME markers to support metabolism studies and early detection of drug-induced liver injury.
Assay-ready human iPSC-derived neuronal subtypes
Subtype-specific neuronal populations (inhibitory and excitatory variants and others) suitable for neuronal electrophysiology, MEA experiments, seizure liability prediction and neurotoxicity assays.
Human iPSC-derived microglia and macrophage populations
Immune-relevant iPSC-derived microglia and macrophage cell types exhibiting functional behaviors such as phagocytosis and cytokine signaling for neuroinflammation and immunotoxicity studies.
Accessory research reagents and assay kits
Range of reagents and kits (antibodies, ELISAs, nucleic acid/exosome purification kits, transfection reagents, media supplements) to support cell-based assays and molecular workflows.
Indexed iPSC repository lines with associated metadata
Cataloged collections of donor-derived iPSC lines with QC metadata, donor consent information and links to associated genomic datasets for research and translational use.
Assay-ready human iPSC-derived cardiomyocytes
Highly pure, terminally differentiated cardiomyocytes produced from human iPSCs and formatted for in vitro safety pharmacology and arrhythmia liability testing; compatible with multielectrode array and other electrophysiology platforms.
Assay-ready human iPSC-derived hepatocytes
Characterized hepatocyte populations derived from iPSCs with genotyping for ADME markers to support metabolism studies and early detection of drug-induced liver injury.
Assay-ready human iPSC-derived neuronal subtypes
Subtype-specific neuronal populations (inhibitory and excitatory variants and others) suitable for neuronal electrophysiology, MEA experiments, seizure liability prediction and neurotoxicity assays.
Human iPSC-derived microglia and macrophage populations
Immune-relevant iPSC-derived microglia and macrophage cell types exhibiting functional behaviors such as phagocytosis and cytokine signaling for neuroinflammation and immunotoxicity studies.
Accessory research reagents and assay kits
Range of reagents and kits (antibodies, ELISAs, nucleic acid/exosome purification kits, transfection reagents, media supplements) to support cell-based assays and molecular workflows.
Indexed iPSC repository lines with associated metadata
Cataloged collections of donor-derived iPSC lines with QC metadata, donor consent information and links to associated genomic datasets for research and translational use.
Services
End-to-end contract development and manufacturing of clinical-grade human cells under cGMP conditions, including licensable GMP iPSC lines, process development, technology transfer, cell banking and CMC/regulatory support.
Custom generation of disease-model iPSC lines from donor samples, genome-edited models (knock-in/knock-out/reporter insertions, SNP engineering) and induced disease-state models delivered with isogenic controls and compatibility for 2D/3D and organ-on-chip integration.
Development and validation of functional assays including electrophysiology (MEA/HD-MEA), contraction-force measurement, high-content imaging, cytokine release assays and metabolic flux assays for preclinical screening and safety pharmacology.
Provision of application protocols, datasheets, user guides, webinars, technical support and a Certificate of Analysis lookup service to aid assay implementation, product selection and lot-specific QC review.
Consortium-based services for development and manufacturing of extracellular vesicle therapeutics, including program support from development through GMP manufacture.
Management and operational guidance for indexed iPSC biobank access including standardized reprogramming, donor consent frameworks, infectious disease screening, QC testing and controlled/open-access genomic data mechanisms.
End-to-end contract development and manufacturing of clinical-grade human cells under cGMP conditions, including licensable GMP iPSC lines, process development, technology transfer, cell banking and CMC/regulatory support.
Custom generation of disease-model iPSC lines from donor samples, genome-edited models (knock-in/knock-out/reporter insertions, SNP engineering) and induced disease-state models delivered with isogenic controls and compatibility for 2D/3D and organ-on-chip integration.
Development and validation of functional assays including electrophysiology (MEA/HD-MEA), contraction-force measurement, high-content imaging, cytokine release assays and metabolic flux assays for preclinical screening and safety pharmacology.
Provision of application protocols, datasheets, user guides, webinars, technical support and a Certificate of Analysis lookup service to aid assay implementation, product selection and lot-specific QC review.
Consortium-based services for development and manufacturing of extracellular vesicle therapeutics, including program support from development through GMP manufacture.
Management and operational guidance for indexed iPSC biobank access including standardized reprogramming, donor consent frameworks, infectious disease screening, QC testing and controlled/open-access genomic data mechanisms.
Expertise Areas
- Human iPSC-derived cell production and differentiation
- Custom disease-model generation and genome engineering
- GMP cell therapy manufacturing and CDMO support
- Large-scale automated cell production and logistics
Key Technologies
- Induced pluripotent stem cell (iPSC) differentiation
- Footprint-free episomal reprogramming
- Genome editing (CRISPR, ZFN, TALEN)
- cGMP cleanroom manufacturing and controlled-environment systems
News & Updates
Announcement of the launch of iCell Sensory Neurons for neuroscience research, drug discovery, and neurotoxicity analysis.
Fujifilm congratulates BlueRock Therapeutics on FDA IND clearance for OpCT-001, an iPSC-derived therapy for primary photoreceptor diseases.
Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities
Fujifilm announces a USD 200 million investment to expand its cell therapy CDMO capabilities.
Announcement of the launch of iCell Sensory Neurons for neuroscience research, drug discovery, and neurotoxicity analysis.
Fujifilm congratulates BlueRock Therapeutics on FDA IND clearance for OpCT-001, an iPSC-derived therapy for primary photoreceptor diseases.
Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities
Fujifilm announces a USD 200 million investment to expand its cell therapy CDMO capabilities.